ERBB2 and urothelial carcinoma: This was in agreement with Yorozu et al. [20] who reported that HER2 protein overexpression and gene amplification were specifically detected in the luminal subtype of urothelial carcinoma of renal pelvis and ureter (UCRPU), suggesting that these patients may benefit from HER2-targeted therapies like trastuzumab.